British biotech startup AstronauTx raises £48m series A financing for Alzheimer’s disease

AstronauTx leads the way in a groundbreaking method for addressing neurodegenerative diseases. Its distinctive collection of small-molecule therapeutics aims to rectify dysregulated physiology, enhancing symptoms and altering the course of the disease. Here are details of AstronauTx’s latest funding round :

🚀 Launch


🏭 Industry



Dr Ruth McKernan (Founder), Dr David Reynolds (Founder), Dr Jamie Bilsland (Chief Scientif Officer), Dr Hannah Pearce (VP of Operations), Dr Keith Wafford (Head of Biology), Dr Daniel Hothersall (Senior Principal Scientist)

💸 Funding & Investors

INVESTMENT (October 2023)£48 million (Series A)
INVESTORSled by the Novartis Venture Fund, the financing was supported by several global venture investors, including Brandon Capital, Bristol Myers Squibb, EQT Life Sciences from the LSP Dementia Fund and MPM Capital with support from the Dementia Discovery Fund.

🎯 Funding purpose

Product development

🌐 Country HQ

UK (London)

Leave a Reply

Your email address will not be published.